Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its ...

Discover why BVNKF's vaccine innovations, growth catalysts, and compelling valuation after a 52% pullback make it a strong ...

Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors’ proposal to transfer the Company’s ...

Yesterday the US Food and Drug Administration (FDA) approved a freeze-dried formulation of Bavarian Nordic's mpox vaccine, ...

Vimkunya is now available in the US for the prevention of disease caused by chikungunya virus in individuals 12 years of age ...

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS ...

In a statement on Thursday, April 10, the Health Cabinet Secretary, Aden Duale, confirmed that the country has received ...

This recent safety and effectiveness data regarding mpox vaccination with Jynneos is important and timely given the ongoing ...

European shares rebounded on Tuesday from a two-month low touched in the previous session, while the market braced for an ...

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US Government to add to vaccine ...

The Company has been contracted by the U.S Biomedical Advanced Research and Development Authority (BARDA) to develop and supply a freeze-dried version of JYNNEOS for stockpiling. Manufacturing under ...

COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS ...